Correlation Between Milestone Pharmaceuticals and Spyre Therapeutics

Can any of the company-specific risk be diversified away by investing in both Milestone Pharmaceuticals and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Milestone Pharmaceuticals and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Milestone Pharmaceuticals and Spyre Therapeutics, you can compare the effects of market volatilities on Milestone Pharmaceuticals and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Milestone Pharmaceuticals with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Milestone Pharmaceuticals and Spyre Therapeutics.

Diversification Opportunities for Milestone Pharmaceuticals and Spyre Therapeutics

0.21

Correlation Coefficient

Milestone Pharmaceuticals  Spyre Therapeutics

Modest diversification

The 3 months correlation between Milestone and Spyre is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Milestone Pharmaceuticals and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and Milestone Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Milestone Pharmaceuticals are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of Milestone Pharmaceuticals i.e., Milestone Pharmaceuticals and Spyre Therapeutics go up and down completely randomly.

Pair Corralation between Milestone Pharmaceuticals and Spyre Therapeutics

Given the investment horizon of 90 days Milestone Pharmaceuticals is expected to generate 0.84 times more return on investment than Spyre Therapeutics. However, Milestone Pharmaceuticals is 1.19 times less risky than Spyre Therapeutics. It trades about 0.2 of its potential returns per unit of risk. Spyre Therapeutics is currently generating about 0.05 per unit of risk. If you would invest  139.00  in Milestone Pharmaceuticals on September 3, 2024 and sell it today you would earn a total of  60.00  from holding Milestone Pharmaceuticals or generate 43.17% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Milestone Pharmaceuticals  vs.  Spyre Therapeutics

Milestone Pharmaceuticals

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Spyre Therapeutics

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Spyre Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Spyre Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Milestone Pharmaceuticals and Spyre Therapeutics

The main advantage of trading using opposite Milestone Pharmaceuticals and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Milestone Pharmaceuticals position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.

The idea behind Milestone Pharmaceuticals and Spyre Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.